The FDA has approved the investigational new drug application (NDA) for Enzon Pharmaceuticals’ HIF-1 alpha antagonist drug.
HIF-1 alpha is a target in many cancer types, including common solid tumours. It is a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells but high intracellular concentrations have been observed in a variety of cancers. High HIF-1 alpha concentrations are correlated with poor prognosis and resistance to therapy.